- Active not recruitingPHASE1
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
This study, MAGNETO, is for children aged 1-16 with neuroblastoma that has come back or not responded to previous treatments. It tests a new type of treatment called GD2 CAR T cells to see if it's safe and can be made successfully. It's an early-stage study.
For: NeuroblastomaUnited Kingdom - RecruitingPHASE1
CAR T Cells to Target GD2 for DMG
This study looks at a new treatment called GD2 CAR T cells for children and young adults aged 2-16 with a type of brain tumour called Diffuse Midline Glioma (DMG). It aims to see if the treatment is safe and how well the body uses it.
For: Diffuse Midline Glioma, H3 K27M-MutantUnited Kingdom